Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

In summary, the UCSF study suggests that extended courses of Paxlovid might help some individuals with long COVID, though ...

A study found that some long COVID patients who took Paxlovid saw improvement. But experts said the research isn't enough to ...

Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Analysts are positive on these five top "strong buy" dividend stocks for this year. They make sense for growth and income ...

A report on the experiences of 13 patients found that the drug had no benefit for some and that some who benefited said the ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating symptoms. Research shows extended Paxlovid treatment could help restore ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer PFE.N COVID-19 treatment Paxlovid, Bristol Myers Squibb's BMY.N cancer cell therapies and vaccines ...

Pfizer Inc. convinced a federal judge in Massachusetts to cancel a patent Enanta Pharmaceuticals Inc. alleges its blockbuster Covid-19 antiviral Paxlovid infringes. Enanta’s changes to the patent, ...